Latest Breaking News On - Urovant sciences gmbh - Page 4 : comparemela.com

Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland

Pierre Fabre Médicament SAS (Pierre Fabre) to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the Europe Economic Area, UK, and Switzerland. Urovant Sciences

United statesUnited kingdomPierre fabreSumitovant biopharmaJim robinsonMaya frutigerEric ducournauAlana darden powellAnne kerveillantUrovant sciences gmbMedia relations pf pharmaceuticals directionCorporate communicationsPierre fabre groupUrovant sciencesSumitovant biopharma ltdHead of corporate communications

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSumitovant biopharmaSumitomo pharmaMaya frutigerAlana darden powellDavid staskinJeffrey frankelDrug administrationAmerican urological associationUrovant sciences incUrovant sciences gmbSeattle urology research centerCorporate communicationsTufts university school of medicineUs public healthUrovant sciences

Urovant Sciences, Inc : Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting

New analyses of data from the Phase 3 EMPOWUR Extension Study of GEMTESA (vibegron) 75 mg provided additional insight into the long-term effects of the product. These data were featured in podium

United statesSumitovant biopharmaSumitomo pharmaMaya frutigerAlana darden powellDavid staskinJeffrey frankelDrug administrationAmerican urological associationUrovant sciences gmbSeattle urology research centerCorporate communicationsTufts university school of medicineUs public healthUrovant sciencesSumitovant biopharma ltd

Urovant Sciences, Inc : Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Interim 12-week analysis from an ongoing Phase 2a trial of an investigational novel gene therapy product (plasmid human cDNA encoding maxi-K channel) showed clinically relevant improvement in the

United statesSumitovant biopharmaKenneth petersSumitomo pharmaMaya frutigerAlana darden powellDepartment of urology at beaumont hospitalAmerican urological associationUrovant sciences gmbCorporate communicationsUs public healthPelvic health centerUrovant sciencesSumitovant biopharma ltdHead of corporate communicationsPlenary presentation

Urovant Sciences, Inc : Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA in Dry and Wet Overactive Bladder Populations

Post-hoc analysis indicates significant reductions in urgency episodes and micturitions in patients treated with GEMTESA vs. placebo in both types of overactive bladder (OAB) Article appears

United statesSumitovant biopharmaSumitomo pharmaSalim mujaisMaya frutigerAlana darden powellJeffrey frankelInternational journal of clinical practiceAboutsumitovant biopharma ltdUrovant sciences gmbSeattle urology research centerSumitomo pharma co ltdCorporate communicationsUrovant sciencesSumitovant biopharma ltdHead of corporate communications